Dobutamine

證據等級: L5

預測適應症: 10 個

Dobutamine: From Acute Heart Failure to Alopecia

One-Sentence Summary

Dobutamine is a synthetic catecholamine and β1-adrenergic agonist, used clinically as an inotropic agent for acute decompensated heart failure and cardiogenic shock. The TxGNN model predicts it may be effective for Alopecia with a score of 99.85%, however no directly relevant clinical trials exist and the only 2 retrieved publications are unrelated to this use. Mechanistic analysis suggests this high-scoring prediction is most likely a knowledge graph artefact rather than a genuine repurposing signal — all 10 predicted indications carry an L5 evidence level and a Hold recommendation.

Quick Overview

Item	Content
Original Indication	Acute heart failure / Cardiogenic shock (short-term inotropic support)
Predicted New Indication	Alopecia
TxGNN Prediction Score	99.85%
Evidence Level	L5
India Market Status	✗ Not marketed (CDSCO)
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on established pharmacology, Dobutamine is a selective β1-adrenergic receptor agonist (with minor β2 and α1 activity) that increases cardiac output by enhancing myocardial contractility and heart rate. It is administered exclusively by continuous intravenous infusion in acute care settings. There is no known biological pathway by which β1-adrenergic stimulation would promote hair follicle growth, arrest follicle miniaturisation, or modulate immune-mediated follicle damage.

Alopecia involves pathological hair loss through diverse mechanisms — immune-mediated T-cell attack on follicles (alopecia areata), androgen-driven follicle miniaturisation (androgenetic alopecia), or structural follicle defects. None of these pathways have an established connection to adrenergic signalling, let alone to β1-selective agonism.

The high TxGNN score almost certainly reflects a knowledge graph artefact: Minoxidil (a well-known topical hair loss treatment) causes cardiac side effects → cardiac toxicity cases may require Dobutamine for haemodynamic support → this indirect path creates an erroneous graph edge linking Dobutamine to hair loss. Both retrieved literature results (PMID 41046802: cat with minoxidil-induced heart failure; PMID 17505274: colchicine-poisoning with incidental hair loss) confirm this interpretation — neither paper involves Dobutamine in the context of treating alopecia. This KG confound appears to propagate across the top 4 ranked predictions, all of which involve hair-related conditions.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

The two retrieved publications for the top-ranked indication (alopecia) are not directly relevant to Dobutamine as a treatment. Both confirm the KG artefact hypothesis described above.

PMID	Year	Type	Journal	Key Findings
41046802	2025	Case Report (Veterinary)	Journal of Veterinary Cardiology	Cat developed left-sided congestive heart failure from minoxidil intoxication; Dobutamine was used for haemodynamic support of hypotension — no connection to alopecia treatment
17505274	2007	Case Report (Pediatric)	Pediatric Emergency Care	Child with acute colchicine poisoning; hair loss appeared in the recovery phase as a known colchicine effect — Dobutamine not involved in alopecia context

Neither publication supports Dobutamine as a treatment for alopecia. These results are consistent with the KG artefact pathway (Minoxidil → cardiac toxicity → Dobutamine rescue) rather than a genuine pharmacological signal.

India Market Information

Dobutamine has no products currently registered with CDSCO and is not marketed in India. There are no authorisation records available for review.

Safety Considerations

Drug Interactions: A total of 99 drug-drug interactions have been identified (source: DDInter). The 20 documented interactions below are all classified as Moderate severity. Notable clustering around antidiabetic agents (GLP-1 agonists, SGLT2 inhibitors, insulins, sulfonylureas) suggests particular vigilance is warranted in patients with concurrent diabetes management.

Interacting Drug	Level	Clinical Class
Acarbose	Moderate	Alpha-glucosidase inhibitor
Albiglutide	Moderate	GLP-1 receptor agonist
Alogliptin	Moderate	DPP-4 inhibitor
Metformin	Moderate	Biguanide
Pioglitazone	Moderate	Thiazolidinedione
Canagliflozin	Moderate	SGLT2 inhibitor
Chlorpropamide	Moderate	Sulfonylurea
Cimetidine	Moderate	H2 receptor antagonist
Dapagliflozin	Moderate	SGLT2 inhibitor
Diethylpropion	Moderate	Sympathomimetic / appetite suppressant
Dulaglutide	Moderate	GLP-1 receptor agonist
Empagliflozin	Moderate	SGLT2 inhibitor
Linagliptin	Moderate	DPP-4 inhibitor
Phentermine	Moderate	Sympathomimetic / appetite suppressant
Repaglinide	Moderate	Meglitinide
Semaglutide	Moderate	GLP-1 receptor agonist
Vancomycin	Moderate	Glycopeptide antibiotic
Insulin aspart	Moderate	Rapid-acting insulin
Insulin degludec	Moderate	Long-acting insulin
Liraglutide	Moderate	GLP-1 receptor agonist

For complete warnings, contraindications, and the full interaction list of 99 agents, please refer to the official package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: All 10 TxGNN-predicted indications for Dobutamine carry an L5 evidence level (model prediction only, no direct supporting studies), and the highest-ranked prediction — alopecia — is assessed as a probable knowledge graph artefact with no mechanistic basis. The drug’s well-established role as an acute intravenous cardiac inotrope is fundamentally incompatible with the dermatological and ophthalmological conditions appearing in the top 10 predictions. Proceeding with any of these indications in their current state would not be scientifically justified.

To proceed, the following would be needed:

KG audit: Confirm and correct the suspected Minoxidil → cardiac toxicity → Dobutamine artefact path in the TxGNN knowledge graph before re-running predictions
MOA data: Retrieve complete mechanism of action from DrugBank API to support any future mechanistic plausibility analysis (Data Gap DG002)
Safety dossier: Download and parse CDSCO/package insert PDF to populate warnings and contraindications (Data Gap DG001 — currently Blocking severity)
Preclinical evidence: Any in vitro or in vivo data linking β-adrenergic signalling to the predicted indication would be required before any clinical consideration
CDSCO registration pathway: If a valid repurposing signal were ever identified, a de novo registration strategy for India would be needed given zero existing market presence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.